NSE: THYROCARE | BSE: 539871

Mid-range Performer

Download real time

461.90 2.70 (0.59%)

110.60% Gain from 52W Low

293.0K NSE+BSE Volume

NSE 05 Jan, 2026 3:31 PM (IST)

7,351.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Thyrocare Technologies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for THYROCARE, BSE:539871 Thyrocare Technologies Ltd.

Thyrocare Technologies Ltd.

12 Mar 2020

461.90

0.59%

Monthly Update - IPM growth not yet impacted by Covid-19

Buy: Thyrocare Technologies Ltd.

Prabhudas Lilladhar

IPM's MAT growth in Feb-20 was 9.7% as against 9.6% in Feb-19 and Jan-20. The growth was majorly contributed by price at 5.4%, volume at 1.9% and new product at 2.5%. In the last 12 months, contributors average growth towards price, volume and new products were 5.6%, 1.7% and 2.3% respectively. The growth attributed by new products and volume however has been on a declining trend in last 50 months, while price hike has been a key factor that has contributed to IPM's growth. With 70-75% intermediaries/API/KSM sourced from China, IPM hasn't been...

Thyrocare Technologies Ltd. is trading above all available SMAs

Thyrocare Technologies Ltd.

09 Mar 2020

461.90

0.59%

Sector Update - Re-emergence of regulatory threat to undermine earnings in near-term

Buy: Thyrocare Technologies Ltd.

Target

Prabhudas Lilladhar

FDA continues to maintain zero tolerance towards injectable units Indian generics ranked 2nd only after US for non-compliance issues of facilities by FDA. With the regulators focus towards approving more generics, Indian majors were short of compliance that led to missed opportunity of launching day-one generics and specialty products in CY19. With USFDA issued WL in CY19 to the Indian majors, the track record of achieving compliance in injectable plant were in shambles as work culture in sterile plant lacked training and integrity. The resolution might take longer than its...

Thyrocare Tech has gained 35.43% in the last 6 Months

Thyrocare Technologies Ltd.

22 Aug 2019

461.90

0.59%

Thyrocare Technologies Ltd: Revenues Enhanced by Volumes Growth

Buy: Thyrocare Technologies Ltd.

Karvy

Thyrocare Q1FY20 earnings came marginally higher than our estimates on account of healthy growth in samples collected

Number of FII/FPI investors increased from 99 to 123 in Sep 2025 qtr.

Thyrocare Technologies Ltd.

14 Aug 2019

461.90

0.59%

Q1FY20 Result Update

Buy: Thyrocare Technologies Ltd.

Target

Prabhudas Lilladhar

diagnostic tests. Overall, Thyrocar increased 10% price for its sick care business in B2B segment while price of few tests in preventive care marginally reduced in Q1FY20. Management guided that the benefits of price rationalization in Aarogyam 1.1, 1.2 and 1.3 will be visible in FY20E. Hence, we expect better traction in volumes and growth in the remaining three quarters of FY20E. Management guided for increased focus on B-2-B business with higher incentives and revenues per franchisee as it focusses...

Thyrocare Technologies Ltd. is trading above all available SMAs

Thyrocare Technologies Ltd.

06 Sep 2017, 12:00AM

461.90

0.59%

Thyrocare Technologies Ltd

Mgmt Note: Thyrocare Technologies Ltd.

ICICI Securities Limited

We met the management of Thyrocare Technologies (Thyrocare) to get an insight into the company's future plans as well as industry dynamics. The company operates mainly in diagnostics and nuclear imaging segments, which contribute 89% and 6% to total revenues, respectively. The diagnostic segment operates on a hub-and-spoke model and currently comprises one automated central processing lab (CPL) in Navi Mumbai and eight regional processing labs (RPL). The samples are aggregated and sent to CPL and RPL from 26 air connected hubs and...

Thyrocare Technologies Ltd. is trading above all available SMAs

Is Thyrocare Technologies Ltd. worth buying?

180 Votes:

Buy 77.22%

Sell 12.22%

Hold 10.56%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf